“A multivalent vaccine targeting the viral hemorrhagic diseases Ebola, Sudan, Marburg and Lassa Fever”

Matthias Schnell, PhD

Professor and Chair, Department of Microbiology and Immunology
Thomas Jefferson University, Philadelphia

Dr. Schnell, PhD, is the Chairman of the Department of Microbiology and Immunology, and the Director of the Jefferson Vaccine Center at Thomas Jefferson University. Dr. Schnell received his Bachelor of Science and Master of Science in Biology at the University of Hohenheim, Stuttgart, Germany and completed his PhD at the Federal Research Center for Virus Diseases of Animals in Tuebingen, Germany. As a graduate student, Dr. Schnell was first to create a negative-stranded RNA virus (NSV), rabies virus (RABV), from cDNA. After finishing his thesis, he extended his studies on NSV as a postdoctoral fellow at Yale University, where he created the first NSV-based vector. After his postdoctoral studies, Dr. Schnell moved to Thomas Jefferson University in 1998 as an Assistant Research Professor in the Department of Biochemistry and Molecular Pharmacology. He became full Professor in 2005. His research is focused on the rabies virus, studying its pathogenicity and interactions with the innate adaptive immunity, as well as studies of viral vectors as vaccines against emerging infectious diseases. His laboratory is highly collaborative, with several national and international projects in viral disease and vaccine research currently ongoing. The vaccine against Ebola virus that was developed in his laboratory has finished the preclinical phase and should enter its first clinical trial in the near future.

Monday,  September 25, 2017

Free Reception:  5:00-6:00 pm
Free Seminar:  6:00-7:00 pm

Bluemle Life Sciences Bldg, Room 101
233 S. 10th Street (10th and Locust St)
Philadelphia, PA 19104

discounted parking at the garage on 11th and Locust Street (entrance on 11th street under Hamilton Building)